Ligand Pharma Grants License to Marinus

Ligand Pharmaceuticals said Wednesday morning it entered into an agreement with Marinus Pharmaceuticals (MRNS) that grants Marinus rights to use its Captisol in the formulation of intravenous ganaxolone. Marinus is planning to start clinical trials with Captisol-enabled ganaxolone in patients with post-partum depression and status epilepticus.

Under the new agreement, which replaces a prior research agreement, Marinus gains exclusive global rights to Captisol-enabled ganaxolone for use in humans. Ligand said it is entitled to potential milestone payments, royalties and revenues from future sales, in addition to an upfront payment.

By Kristen Tardella